Splenic irradiation as palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis: a multi-institutional experience
Pistevou-Gombaki, K.; Zygogianni, A.; Kantzou, I.; Kyrgias, G.; Mystakidou, K.; Kouvaris, J.; Klonizakis, I.; Tsirigotis, P.; Pappa, V.; Siakantari, M.; Eleftheriadis, N.; Georgakopoulos, J.; Sarris, G.; Kelekis, N.; Kouloulias, V.
Journal of BUON Official Journal of the Balkan Union of Oncology 20(4): 1132-1136
2015
ISSN/ISBN: 1107-0625 PMID: 26416067 Document Number: 679558
To evaluate the impact of splenic irradiation as a palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis. Seventeen patients with chronic myelogenous leukemia and 3 with idiopathic polycythaemia presented with splenomegaly, splenic pain and anemia. Due to symptomatic splenomegaly, despite first-line treatment, the patients underwent splenic irradiation. Two patients received two different schedules of external radiotherapy (580 cGy in 5 fractions and 600 cGy in 6 fractions). Eight patients received 980 cGy in 14 fractions. Ten patients received two courses of 360 cGy in 6 fractions, 3 months apart. Median follow-up was 12 months post irradiation. The patients showed excellent response to treatment one month post-radiotherapy, while treatment was well tolerated without severe toxicity. The dimensions of the spleen decreased significantly. Pain-related Visual Analogue Score (VAS) regressed after completion of irradiation. During 12-month follow-up all patients maintained the benefit of radiotherapy. This study indicates that splenic irradiation could be a safe and effective palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis.